#BEGIN_DRUGCARD DB00632

# AHFS_Codes:
84:04.06

# ATC_Codes:
D06BB11

# Absorption:
Topical absorption has been shown to be minimal under conditions reflecting normal clinical use.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Abreva

# CAS_Registry_Number:
30303-65-2

# ChEBI_ID:
31000

# Chemical_Formula:
C22H46O

# Chemical_IUPAC_Name:
docosan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2245677

# Description:
Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication.

# Dosage_Forms:
Cream	Topical

# Drug_Category:
Antiviral Agents
Dermatologicals

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
9

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Docosanol

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3

# InChI_Key:
InChIKey=NOPFSRXAKWQILS-UHFFFAOYSA-N

# Indication:
For the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
632

# Mechanism_Of_Action:
Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV.

# Melting_Point:
65-72 Â°C

# Molecular_Weight_Avg:
326.6

# Molecular_Weight_Mono:
326.354866094

# Organisms_Affected:
Herpes simplex virus

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164749211

# Pharmacology:
Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol cannot, however, prevent cold sores or fever blisters from appearing.

# Predicted_LogP_Hydrophobicity:
9.31

# Predicted_LogS:
-7.2

# Predicted_Water_Solubility:
1.96e-05 g/l

# Primary_Accession_No:
DB00632

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
12620

# PubChem_Substance_ID:
46508049

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00933

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCCCCCCCCCCCCCCCCCCCO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Behenyl alcohol

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include headache, abdominal pain, increased serum lipase, nausea, dyspepsia, dizziness, and hyperbilirubinemia.

# Update_Date:
2013-02-08 16:19:30 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Docosanol

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Virion
virion membrane. Most abundant component of the viral envelope

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15571473	Leung DT, Sacks SL: Docosanol: a topical antiviral for herpes labialis. Expert Opin Pharmacother. 2004 Dec;5(12):2567-71.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
20210688	Treister NS, Woo SB: Topical n-docosanol for management of recurrent herpes labialis. Expert Opin Pharmacother. 2010 Apr;11(5):853-60.
9864049	Pope LE, Marcelletti JF, Katz LR, Lin JY, Katz DH, Parish ML, Spear PG: The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res. 1998 Dec;40(1-2):85-94.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
V01555

# Drug_Target_1_GenBank_ID_Protein:
1334868

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
BLLF1

# Drug_Target_1_Gene_Sequence:
>2724 bp
TTATACATAGGTCTCGGCGTCATCATATGGTGGGGTGGTGTAGGTATGGGATGTAGACAA
GTTACGCCTAAAGGCGCAGTCCGCCATGACCAGCAGCAGCAGAAGGGTCAGCACAGCCAG
AGAGGCCCACTGCAGTACTAGCATGGAGAGGTTTGAGAATCTGGGCTGGGACGTTGGCGG
GACTGGCACGGTGGCTTGGGCTGTGGTAACCGGTGGGCTCGTAAAAGTCCAGCGGGGCCG
CAGTTTGCTAGAAGTGCTGGGAGGTAGATAGGTGGTCGCATTGTATCTCGGTCTTGGCGT
AGTTGAATCACCGCCGTAATCTGTGGTGGGCTCTGTACTTGTCCGGGCTCCATGTCCTGT
GGTGTGCTTTCCACCGGTGGTAGAATTGGCCTTTCCACCTGTTGAGGTGACCGTGGGAAC
CGCCGTCTTTTGGCCACTGGGGGCCTGGGGCGACGTTGCATTTTGGGGGGGCGTGCCTTT
GGTGACATTAACCTCCCCCGGTTTTGTGGATGTGGAACTGTTTCCAGGGCCTGACGCTTG
GCTGGTGGTGCCTGGGCGGGGTGCTGGCGAACTGGTGGACACATGATGTGTGCTGATAGA
GGCTGGTGTCACCTGTGTTATATTTTCACCACCTGTTGGGTGAGCGGAGGTTAGTAAAGG
CATATGTGACGTTGAATTGTCACTGGTGGAGGGGCTGAGTGTCTCTGGGTTTGAACTGGG
TCTCAGTGACATGGAAGAGGTTGAACTTGAAGTTATGTTATGTTGGCCTGTGGTAACAGC
ACTGGTTGCATTTTTTGGTTGGCTGGTAACTACTGGGGTGGGACTTGTTCCTCCTAAGGT
GTGGTTGGTGGCATTTGCCTGTGGACTTGTTTCTCCCACAGTAGGGCCGGTGGCATTTGG
GGTTGGGGTAGTCACTGCTGAGGTGGGGCTTGTTTTTCCCAAGGTGGGGCTGGTGGCATT
TGGGGTTGGGGTAGTCACTGCTGAGGTGGGGCTTGTTTTTCCCAAGGTGGGGCTGGTGGC
ATTTGGGGTTGGGGTAGTCACTGCTGAGGTAGGACTTGTTTTTCCCAAGGTGGGGCTGGT
GGCATTTGGGGTTGGGGTAGTCACTGCTGGGGTGGGGCTGGTGGCATTTGGGGTTGGGGT
AGTCACTGCTGGGGTGGGGCTGGTGGCATTTGGGGTTGGGGTAGTCACTGGTGAGGTGGA
GCTGGTCATGTCGGGGGCCTTACTTTCTGTGCCGTTGTCCCATGGAGATGGACTTGGTGT
CACCGGTGATGCGCCTGACGTTGTGCCGGCTGGTGTTGGGCTGGTGACATCCGCGGTGGA
TACAGTGGGGCCTGTGCTTGCAGGTGCGGTGAGGTTGGTAGGCACGTGAGTAGAGCTGGG
TAGACCTGTCGTTGTATTGGGATCAGCAAATCCAGTTGTATTCAAGGTAGGGGAGGTGGT
GGTGCTCTCGGGTGCCTTGGAGAATATAACCTTGTGGGTTGTTGTGGTGGCATTGGTAGC
CGTTCGTGTGATAATGAGTGTCTTGGGGGCCGTGCCAAGACCCGAGACAGTAATGTCAAA
TGTCCGATTGCTCGCAAATGCACCAGAAATATTTTCACAACCCGAAGGTGTCCCCGAGGT
GAGAGTCCATTTGCACTTAAAGTCAGTTTCAGTGTTGTTTGGCCAGGCCCAAAAGGCAGT
CACTGTAACATTTGGCGAGTTTGCGTCCTCAGAAGTGACCATTGGCACTGAATAGGTAGC
ATTGTCACCCACATATGTGATGTCTGTGGTGTTTGTCGGCATGTCCTGTGAAGCTGGAAT
CTCATCAGAGAACACAATGTTGGACTGAATGCAGTAATCTCCCCCGCTCGCCTTCGGTCC
ATTCCCAGAGTAAAACACGTACAGGATACTGTTATTGCCAAGAAATCGTGACACTGGACG
TGGTGTCAGACGCAGGCTGTATGCATACCCTGTACCAGGTATTGGGGTGGCCACGGGACT
CGTTGATGTGAGAATTCCGCCGCTGGGAACATGGCTCTCGTATCCACTGCAGGTGATGTT
AAATTTGTTGTCTCCGGGCAGAACTTGTGAAATTTCGCCATCCTCCATAATACACTCAAT
ATCTATCTCATTACCGAGCATTTCTGTTTTTACGCTGAAATTCGAGTCTTGAGCTGACGT
TGGCAAACTTAAGGGTAGCGTGACATCCAGCCCCTGTGCCCTCACTACTGCCGTTATATT
GGTAGAATTACAGTTATCCCACTTTATGTATGGCACTGTTTCTGGTATCAGGTACACGGG
GTTTTGCATTTCTGCATGGTGGCACCACATGGTTCCAAACACATCTTGAAAGTAGACATC
TACAGATTCCAGGCTTACTTGTTGCTCCTCTCCGGTGGTGACGTTAATTGGAAGCTTCTT
AGACCGCATAGTTAGAGCCAATTCTCCTGCACCAAGGAGCTCCAGTAGAAAGAGATTGGT
GGCATTTTCTGAGCCACCAAATGCACCTCGAGGTTGGTAGACAGCCTTCGTATGGGGTGT
CAGCTGGCCAAAGTCAAGATCAAGTTGATGCTTTTTGCCCCCGACATCGAAATTGATAGT
TACATTGACATCTGCCGTGCAAACATTGCATGTGGGGTAAAATGGGAATTCCGGAATCTC
AACATTGAAAAAACCAGGATCTTCACCCGTGAGATGGATCAGGCTCTGGATGGTGTACTG
ACACACAAGCAAGGCTGCCTCCAT

# Drug_Target_1_General_Function:
Transcription

# Drug_Target_1_General_References:
6087149	Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C, et al.: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984 Jul 19-25;310(5974):207-11.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
653

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
94432

# Drug_Target_1_Name:
Envelope glycoprotein GP340/GP220

# Drug_Target_1_Number_of_Residues:
907

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF05109	Herpes_BLLF1

# Drug_Target_1_Protein_Sequence:
>Envelope glycoprotein GP340/GP220
MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQ
LDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEE
QQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLD
VTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVP
SGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQ
SNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTET
DFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVI
FSKAPESTTTSPTLNTTGFADPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAG
TTSGASPVTPSPSPWDNGTESKAPDMTSSTSPVTTPTPNATSPTPAVTTPTPNATSPTPA
VTTPTPNATSPTLGKTSPTSAVTTPTPNATSPTLGKTSPTSAVTTPTPNATSPTLGKTSP
TSAVTTPTPNATGPTVGETSPQANATNHTLGGTSPTPVVTSQPKNATSAVTTGQHNITSS
STSSMSLRPSSNPETLSPSTSDNSTSHMPLLTSAHPTGGENITQVTPASISTHHVSTSSP
APRPGTTSQASGPGNSSTSTKPGEVNVTKGTPPQNATSPQAPSGQKTAVPTVTSTGGKAN
STTGGKHTTGHGARTSTEPTTDYGGDSTTPRPRYNATTYLPPSTSSKLRPRWTFTSPPVT
TAQATVPVPPTSQPRFSNLSMLVLQWASLAVLTLLLLLVMADCAFRRNLSTSHTYTTPPY
DDAETYV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Responsible for EBV binding to the CR2 receptor on human B-cells

# Drug_Target_1_SwissProt_ID:
P03200

# Drug_Target_1_SwissProt_Name:
VGP3_EBVB9

# Drug_Target_1_Synonyms:
MA
Membrane antigen

# Drug_Target_1_Theoretical_pI:
5.42

# Drug_Target_1_Transmembrane_Regions:
863-885

# Drug_Target_2_Cellular_Location:
Virion
virion membrane. Most abundant component of the viral envelope

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15571473	Leung DT, Sacks SL: Docosanol: a topical antiviral for herpes labialis. Expert Opin Pharmacother. 2004 Dec;5(12):2567-71.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
L07922

# Drug_Target_2_GenBank_ID_Protein:
291520

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
BLLF1

# Drug_Target_2_Gene_Sequence:
>2661 bp
TTATACATAGGTCTCGGCGTCATCATATGGTGGGGTGGTGTAGGTATGGGATGTCGACAA
GTTACGCCTGAAGGCGCAGTCCGCCATGACCAGCAGCAGCAGAAGGGTCAGCACCGCCAG
AGAGGCCCACTGCAGTACTAGCATGGAGAGGTTTGAGAATCTGGGCTGGGACGTTGGCGG
GACAGGCACGGTGGCTTGGGCTGTGGTAACCGGTGGGCTCGTAAAAGTCCAGCGGGGCCG
CAGTTTGCTAGAAGTGCTGGGAGGTAGATAGGTGGTCGCATTGTATCTCGTTCTTGGCGT
AGTTGAATCACCGCCGTAATCTGTGGTGGGCTCTGTACTTGTCCGGGCTCCATGTCCTGT
GGTGTGCTTTCCACCGGTGGTAGAATTGGCCTTTCCACCTGTTGAGGTGACCGTGGGAAC
CGCCGTCTTTTGGCCACTGGGGGCCTGGGGCGACGTTGCATTTTTGGGGGGCGTGCCTTT
GGTGACATTAACCTCCCCCGGTTTTGTGGATGTGGAACTGTTTCCAGGGCCTGACGCTTG
GCTGGTGGTGCCTGGGCGGGGCGCTGGCGAACTGGTGGACACATGATGTGTGCTGGTAGA
GGCTGGTGTCACCTGTGTTATATTTTCACCACCTGTTGGGTGAGCGGAGGTTAGTAAAGG
CATATGTGACGTTGAATTGTCACTGGTGGAGGGGCTGAGTGTCTCTGAGATTGAACTGGG
TCTCAGTGACATGGAAGAGGTTGAACTTGAAGTTATGTTATGTTGGCCTGTGGTAACAGC
ACTGGTTGCATTTTTTGGTGGGCTGGTAACTACTGGGGTGGAACTTGTTCCTCCTAATGT
GTGGTTGGTGGTATTTGCCTGTGGACTTGTTTCTCCCACAGTAGGGCTGGTGGCATTTGG
GGTTGGGGTAGTCACTGCTGAGGTGGGACTTGTTTTTCCCAAGGTGGGGATGGTGGCATT
TGGGGTTGGGGTAGTCACTGCTGGGGTGGGGCTGGTGGCATTTGGGGTTGGGGTAGTCAC
TGCTGAGGTGGGACTTGTTTTTCCCAAGGTGGGGCTGGTGGCATTTGGGGTTGGGGTAGT
CACTGCTGGGGTGGGGCTGGTGGCATTTGGGGTTGGGGTAGTCACTGCTGAGGTGGGGCT
GGTCATGTCGGGGGCCTTACTTTCTGTGCCGTTGTCCCGTGGAGATGGACTTGGTGTCAC
CGGTGATGCGCCTGACGTTGTGCCGGCTGGTGTTGGGCTGGTGACATCCGCGGTGGATAC
AGTGGGGCCTGTGCTTGCAGGTGCGGTGAGGTTGGTAGGCACGTGAGTAGAGCTGGGTAG
ACCTGTCGTTGTATTGGGAGCAGCAAATCCAGTTGTATTCAAGGTAGGGGAGGTGGTGGT
GCTCTCGGGTGCCTTGGAGAATATAACCTTGTGGGTTGTTGTGGTGGCATTGGTAGCCGT
TCGTGTGATAATGAGTGTCTTGGGGGCCGTGCCAAGACCCGAGACAGTAATGTCAAATGT
CCGATTGCTCGCAAATGCACCAGAAATATTTTCACAACCCGAAGGTGTCCCCGAGGTGAG
AGTCCATTTGCACTTAAAGTCAGTTTCAGTGTTGTTTGGCCAGGCCCAAAAGGCAGTCAC
TGTAACATTTGGCGAGTTTGCGTCCTCAGAAGTGACCATTGGCACTGAATAGGTAGCATT
GTCACCCACATATGTGATGTCTGTGGTGTTTGTCGGCATGTCCTGTGAAGCTGGAATCTC
ATCAGAGAACACAATGTTGGACTGAATGCAGTAATCTCCCCCGCTCGCCTTCGGTCCATT
CCCAGAGTAAAACACGTACAGTATACTGTTATTGCCAAGAAATCGTGACACTGGACGTGG
TGTCAGACGCAGGCTGTATGCATACCCTGTACCAGGTATTGGGGTGGCCACGGGACTCGT
TGATGTGAGAATTCCGCCGCTGGGAACATGGCTCTCGTATCCACTGCAGGTGATGTTAAA
TTTGTTGTCTCCGGGCAGAACTTGTGAAATTTCGCCATCCTCCATAATACACTCAATATC
TATCTCATTACCGAGCATTTCTGTTTTTACGCTGAAATTCGAGTCTTGAGCTGATGTTGG
CAAACTTAAGGGTAGCGTGACATCCAGCCCCTGTGCCCTTACTACTGCCGTTATATTGGT
AGAATTACAGTTATCCCACTTTATGTATGGCACTGTTTCTGGTATTAGGTATACTGGGTT
TTGCATTTCTGCATGGTGGCACCACATGGTGCCAAACACATCTTGAAAGTAGACATCTAC
AGATTCCAGGCTTACTTGTTGCTCCTCTCCGGTGGTGATGTTAATTGGAAGCTTCTTAGA
CCGCATAGTTAGAGCCAATTCTCCTGCACCAAGGAGCTCCAGTAGAAAGAGATTGGTGGC
ATTTTCTGAGCCACCAAATGCACCTCGAGGTTGGTAGACAGCCTTTGTATGGGGTGTCAG
CAGGCCAAAGTCAAGATTAAGTTTATGCTTTTTGCCCCCGACATCGAAATTGATAGTTGC
ATTGACATCTGCCGTGCAAACATTGCACGCTGGGTAAAATGGGAATTCCAGAATCTCAAC
ATTGAAAAAACCAGGATCATCACGCGTGAGTTGGATAAGGCTCTGGATGGTGTACTGACA
CACAAGCAAGGCTGCCTCCAT

# Drug_Target_2_General_Function:
Transcription

# Drug_Target_2_General_References:
8393237	Lees JF, Arrand JE, Pepper SD, Stewart JP, Mackett M, Arrand JR: The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B. Virology. 1993 Aug;195(2):578-86.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
786

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
92389

# Drug_Target_2_Name:
Envelope glycoprotein GP340

# Drug_Target_2_Number_of_Residues:
886

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF05109	Herpes_BLLF1

# Drug_Target_2_Protein_Sequence:
>Envelope glycoprotein GP340
MEAALLVCQYTIQSLIQLTRDDPGFFNVEILEFPFYPACNVCTADVNATINFDVGGKKHK
LNLDFGLLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINITTGEE
QQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLD
VTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVP
SGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQ
SNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTET
DFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVI
FSKAPESTTTSPTLNTTGFAAPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAG
TTSGASPVTPSPSPRDNGTESKAPDMTSPTSAVTTPTPNATSPTPAVTTPTPNATSPTLG
KTSPTSAVTTPTPNATSPTPAVTTPTPNATIPTLGKTSPTSAVTTPTPNATSPTVGETSP
QANTTNHTLGGTSSTPVVTSPPKNATSAVTTGQHNITSSSTSSMSLRPSSISETLSPSTS
DNSTSHMPLLTSAHPTGGENITQVTPASTSTHHVSTSSPAPRPGTTSQASGPGNSSTSTK
PGEVNVTKGTPPKNATSPQAPSGQKTAVPTVTSTGGKANSTTGGKHTTGHGARTSTEPTT
DYGGDSTTPRTRYNATTYLPPSTSSKLRPRWTFTSPPVTTAQATVPVPPTSQPRFSNLSM
LVLQWASLAVLTLLLLLVMADCAFRRNLSTSHTYTTPPYDDAETYV

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Responsible for EBV binding to the CR2 receptor on human B-cells

# Drug_Target_2_SwissProt_ID:
P68344

# Drug_Target_2_SwissProt_Name:
VGP3_EBVP3

# Drug_Target_2_Synonyms:
MA
Membrane antigen

# Drug_Target_2_Theoretical_pI:
5.96

# Drug_Target_2_Transmembrane_Regions:
842-864

#END_DRUGCARD DB00632
